Abstract: Disclosed are degradable materials including molded products, laminates, foams, nonwoven materials, adhesives, coatings and films, and particularly packaging films. The materials are made using polydioxaneone polymers comprising at least two different dioxaneone-based repeating units. Preferred polymers are polydioxanediones. First repeating units have less carbon atoms in constituent groups extending from the polymer backbone than second repeating units. Physical characteristics and degradation of the materials can be varied by varying the choice and/or relative proportions of first and second repeating units in the polydioxaneone polymers. Methods for preparing polydioxaneone polymers that can be used in the manufacture of the materials are also discussed, as are suitable monomers and methods for preparing such monomers.

Abstract: There are described compounds of the formula I ##STR1## in which the substituents R(1) to R(7) and X have the meanings shown in the claims, and their pharmaceutically tolerable salts. These are effective inhibitors of the cellular sodium proton antiporter (Na.sup.+ /H.sup.+ exchanger). They are therefore outstandingly suitable for the treatment of all diseases which can be attributed to increased Na.sup.+ /H.sup.+ exchange.

Abstract: Selected novel substituted pyridine compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Abstract: The present invention relates to a novel benzoyl urea derivative which exhibits potent growth-retarding activity against pests and which is represented by formula (I), ##STR1## in which A represents N or CH, and X.sup.1 and X.sup.2 independently of one another represent hydrogen, fluoro, chloro or bromo.

Abstract: Disclosed is a method for the inhibition of binding of a ligand to an RNA, the inhibition being mediated by a small organic molecule that binds to the RNA, thereby inhibiting ligand binding. A preferred class of small organic molecules are compounds exemplified by 2,5-Bis[3-(2-N,N-dimethylaminopropylamidino)phenyl]furan.

Abstract: Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the picornaviral 3C protease. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.

Abstract: Radiation- or thermally-initiated cationically-curable compounds based on styrene oxide moieties are linked to organic molecules, oligomers or polymers.

Abstract: An improved method of making an olefin polymerization catalyst is disclosed. The method reacts essentially equimolar amounts of a Group 4 transition metal tetrahalide and a quinolinol or pyridinol in the presence of a C.sub.5 -C.sub.10 hydrocarbon at a temperature within the range of about 0.degree. C. to about 60.degree. C. The method gives high yields of quinolinoxy or pyridinoxy-substituted Group 4 transition metal trihalides in a single reaction step. Particularly when combined with an activator, the target compounds are excellent olefin polymerization catalysts.

Abstract: A novel fluorinated hydrocarbon compound containing an oxygen or sulfur atom in its molecule, produced by the nucleophilic reaction of a fluorine compound with a hydrocarbon compound. This compound is useful as a lubricant for various applications and particularly excellent as an oil for refrigerators wherein hydrochlorofluorocarbon is used as the refrigerant and as a magnetic recording medium lubricant.

Abstract: The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Abstract: The instant invention provides processes for preparing compounds of formula IV, V, and IX, having the structures provided hereinbelow: ##STR1## These compounds are useful intermediates in the further preparation of benzo[b] thiophenes.

Abstract: Novel nonpeptides characterized as having a carbamic group which are antagonists of endothelin I are described, as well as methods for their preparation and pharmaceutical compositions containing the same. The compounds are useful in treating elevated levels of endothelin and are therefore useful in the treatment of hypertension, myocardial infarction, diabetes, cerebral vasospasm, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythminas, asthma, chronic and acute renal failure, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, stroke, head injury, and ischemic bowel syndrome.

Abstract: A class of 4,7-dichlororhodamine compounds useful as fluorescent dyes are disclosed having the structure ##STR1## wherein R.sub.1 -R.sub.6 are hydrogen, fluorine, chlorine, lower alkyl, lower alkene, lower alkyne, sulfonate, sulfone, amino, amido, nitrile, lower alkoxy, linking group, or combinations thereof, or, when taken together, R.sub.1 and R.sub.6 is benzo, or, when taken together, R.sub.4 and R.sub.5 is benzo; Y.sub.1 -Y.sub.4 are hydrogen or lower alkyl, or, when taken together, Y.sub.1 and R.sub.2, Y.sub.2 and R.sub.1 Y.sub.3 and R.sub.3, or Y.sub.4 and R.sub.4 is propano, ethano, or substituted forms thereof; and X.sub.1 -X.sub.3 taken separately are selected from the group consisting of hydrogen, chlorine, fluorine, lower alkyl, carboxylate, sulfonic acid, --CH.sub.2 OH, and linking group. In another aspect, the invention includes reagents labeled with the 4,7-chlororhodamine dye compounds, including deoxynucleotides, dideoxynucleotides, and polynucleotides.

Abstract: Provided is a compound having an oxetanyl group and represented by the following formula: ##STR1## wherein R.sub.1 represents a methyl group or an ethyl group and R.sub.2 represents a hydrogen atom, a halogen atom, a straight or branched chain alkyl group of 1-5 carbon atoms, an unsubstituted or substituted phenyl group, an unsubstituted or substituted phenoxymethyl group, an unsubstituted or substituted phenoxypropyl group or an unsubstituted or substituted phenyl group. A process for producing the compound and a curing composition comprising the compound and a cationic polymerization initiator are also provided.

Abstract: The invention provides a cationic polynucleoside chain having multiple nucleosides, the nucleosides being coupled together by positively charged guanidyl linkages.

Abstract: Solid solutions comprising quinacridone and 6,13-dihydroquinacridone are prepared by oxidation of a finely divided 6,13-dihydroquinacridone salt in an aqueous basic alcoholic medium using hydrogen peroxide as the oxidant. The solid solutions are useful as red organic high performance pigments.

Abstract: The invention relates to a process for the preparation of compounds of the general formula I ##STR1## in which R.sup.1 and R.sup.2 are identical or different and are a C.sub.1 -C.sub.20 -alkyl group, C.sub.3 -C.sub.12 -cycloalkyl group, C.sub.7 -C.sub.12 -aralkyl group or a mono- or binuclear aryl group, in which a ketone of the formula III or IV ##STR2## in which R.sup.1 and R.sup.2 have the above meaning, is asymmetrically hydrogenated.

Abstract: For the synthesis of 3-methylnaltrexone from codeine in this invention, codeine is converted to 6-acetylcodeine, which is N-demethylated to 6-acetylcodeine hydrochloride, followed by alkylating the nitrogen to form 17-cyclopropylmethylnorcodeine. The latter is oxidized to 17-cyclopropylmethylnorcodeinone. For the synthesis of naltrexone from morphine in this invention, morphine is converted to 3-benzylnormorphine as described above in the synthesis of noroxymorphone. 3-Benzylnormorphine is reacted with cyclopropylmethyl halide to produce 3-benzyl-17cyclopropylmethylnormorphine, a novel compound, which is oxidized to 3-benzyl-17-cyclopropylmethyl-normorphinone, a novel compound, by Swern oxidation.

Abstract: A process is provided for preparing oxycodone from codeine comprising either:(A) the steps of(1) oxidizing codeine so as to form codeinone;(2) converting codeinone to oxycodone in a two-step-one-pot reaction: first reacting codeinone with hydrogen peroxide in water in the presence of an acid at from about 15.degree. to about 70.degree. C. to form 14-hydroxycodeinone and then catalytically hydrogenating 14-hydroxycodeinone in its original reaction mixture to form oxycodone; or(B) the steps of(1) oxydizing codeine so as to form codeinone;(2) reacting codeinone with an acylating agent so as to form codeinone dienol acylate;(3) oxidizing codeinone dienol acylate with an oxidation agent in water or a solubilizing solvent mixture in the presence of an acid at from about 15.degree. to about 70.degree. C. to form 14-hydroxycodeinone;(4) hydrogenating 14-hydroxycodeinone in its original reaction mixture to form oxycodone.

Abstract: The invention relates to the trihydrate of the mesylate salt of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propano l, pharmaceutical compositions containing said compound and methods of treating disorders of the central nervous system by administering said compound.